Gold nanoclusters for Parkinson's disease treatment

Biomaterials. 2019 Feb:194:36-46. doi: 10.1016/j.biomaterials.2018.12.013. Epub 2018 Dec 13.

Abstract

Drug discovery for Parkinson's disease (PD) is challenging. Here we report that gold nanoclusters (AuNCs) can serve as a novel candidate for the design of anti-PD drugs. With N-isobutyryl-l-cysteine (L-NIBC) protected AuNCs as an example, we show that AuNCs effectively prevent α-Synuclein (α-Syn) fibrillation in in vitro experiments. Cell experiments demonstrate good neuroprotective effects in PD cell models. More significantly, experiments of mouse PD model further show that AuNCs largely ameliorate the behavioral disorders of sick mice. In addition, immunohistochemical and western blot (WB) analyses indicate that AuNCs can significantly reverse dopaminergic (DA) neuron loss in substantia nigra and striatum of sick mice. This study opens up a novel avenue to develop anti-PD drugs and points a new direction for AuNCs in medicinal applications.

Keywords: Anti-PD drugs; Gold nanoclusters; Medicinal application; Mouse PD model; Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / therapeutic use*
  • Cysteine / analogs & derivatives*
  • Cysteine / therapeutic use
  • Disease Models, Animal
  • Gold / therapeutic use*
  • Male
  • Mice, Inbred C57BL
  • Nanoparticles / therapeutic use*
  • PC12 Cells
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / therapy
  • Rats
  • alpha-Synuclein / metabolism

Substances

  • Antiparkinson Agents
  • alpha-Synuclein
  • N-isobutyrylcysteine
  • Gold
  • Cysteine